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CLL stereotyped subset #2 (IGHV3-21/IGLV3-21) is uniformly aggressive independently of somatic
hypermutation status.
The prognosis for non–subset #2/IGHV3-21 CLL resembles that of the remaining CLL cases with
similar somatic hypermutation status.

Abstract
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general,
or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV321), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593
CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.
Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non–
subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly
shorter time-to-first-treatment (TTFT) compared with non–subset #2/IGHV3-21 (22 vs 60 months, P =
.001). No such difference was observed between non–subset #2/IGHV3-21 vs the remaining CLL with
similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a
homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive,
contrasting non–subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the
remaining CLL.

Introduction
The somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) genes is one of
the most robust prognostic markers in chronic lymphocytic leukemia (CLL), allowing the identification of
2 groups with markedly different behavior. Those with no or few somatic mutations (“unmutated,” UCLL) experience an aggressive disease, whereas those with a heavier SHM load (“mutated,” M-CLL)
follow more indolent disease courses.1,2
However, patient stratification into M-CLL and U-CLL should not be unconditional: indeed, cases with
borderline IGHV germline identity (GI) should be evaluated and characterized with caution because they
comprise a mixture of indolent and aggressive cases.3-6 Moreover, cases with particular B-cell receptor
immunoglobulin (BcR IG; eg, those expressing specific IGHV genes) have been reported to not abide by
the M-CLL/U-CLL categorization rule.7-9 A paradigmatic example concerns IGHV3-21 gene usage,
which has been correlated with shorter overall survival (OS) independently of SHM status.10-12
Interestingly, more than half of CLL cases utilizing the IGHV3-21 gene display highly similar variable
heavy complementarity determining region 3 (VH CDR3) sequences and light-chain gene usage9-14; thus,
they fulfill the criteria of BcR IG stereotypy, a frequent phenomenon in CLL, occurring in ∼30% of
patients. These IGHV3-21-stereotyped cases form the largest stereotyped subset within CLL, namely
subset #2 (∼3% of all CLL),15 with a distinctive biological profile.16-18 Realizing that subset #2 represents
such a major fraction of IGHV3-21 CLL inevitably raised questions about the relative prognostic
significance of IGHV3-21 gene usage per se as opposed to subset #2 membership. Put differently, is it the
specific gene or the particular stereotyped BcR IG that is linked to clinical aggressiveness?
Previous studies seeking answers to this question have reached quite contradictory results, likely because
of the small cohort sizes and the different end points (time to first treatment [TTFT] and/or
OS).10,11,13,14,19,20 Although the jury is still out, IGHV3-21 gene usage is notably considered a feature of
high-risk CLL and taken into consideration in the context of prospective clinical trials (NCT01243190,
NCT01269385, NCT01625741, NCT00562328), clearly indicating the need for careful reappraisal, which
is the focus of our study.

Study design
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Patients
Overall, 8593 CLL patients were included in the study (supplemental Table 1, available on the Blood Web
site). The study was approved by the local Ethics Review Committees.
Biological markers
Interphase fluorescence in situ hybridization, CD38 and zeta-associated protein 70 (ZAP70) expression,
polymerase chain reaction amplification, sequence analysis, and interpretation of IGHV-IGHD-IGHJ
rearrangements, including stereotyped subset assignment, were performed as reported21-23 (see also
supplemental Methods).
Statistical analysis
Differences in frequencies were evaluated using descriptive statistics. OS was measured from the date of
diagnosis until the last follow-up or death, whereas TTFT was evaluated from the diagnostic date until the
date of initial treatment. Survival curves were constructed with the Kaplan-Meier method, and the log-rank
test was used to determine differences between survival proportions. Multivariate Cox regression models
were used to test the simultaneous effect of factors on outcomes taking into account the relative effect of
remaining parameters. All statistical analyses were performed using Statistica Software 10.0 (Stat Soft
Inc., Tulsa, OK).

Results and discussion
Within our series, 437/8593 cases (5%) expressed IGHV3-21 BcR IG. Of these, 254 (58%) were assigned
to subset #2 as they shared homologous VH CDR3 sequences of identical length,15 whereas the remaining
183 (42%) IGHV3-21-expressing cases exhibited heterogeneous VH CDR3 lengths and amino acid
composition (“non–subset #2/IGHV3-21”; supplemental Table 2).
No differences were observed between subset #2 vs non–subset #2/IGHV3-21 cases regarding age at
diagnosis, gender distribution, CD38 and ZAP70 expression, or cytogenetic abnormalities detected by
fluorescence in situ hybridization; subset #2 was enriched for Binet B/C cases (Table 1 and supplemental
Table 3). Both groups exhibited mixed SHM status (ie, were composed of both M-CLL and U-CLL);
however, non–subset #2/IGHV3-21 cases had overall a significantly lower (P = .002) SHM load, with 53%
(97/183) of the non–subset #2/IGHV3-21 cases composed of U-CLL as opposed to 39% (98/254) of subset
#2 cases. Subset #2 was enriched for cases with borderline identity (97% to 97.99%), whereas non–subset
#2/IGHV3-21 M-CLL cases carried a heavier SHM load, more frequently displaying IGHV GI below 97%
(supplemental Table 2A).
In order to avoid the possible confounding effects of different treatments, survival analysis was restricted
to assessing TTFT in 6744 cases with treatment information (IGHV3-21: n = 355, 5.2%). Subset #2
exhibited a short median TTFT of 22 months, similar to all non-IGHV3-21 U-CLL (24 months, P = ns).
Within subset #2, gender, CD38 or ZAP70 expression, the presence of del(13q) or del(17p), and also SHM
status had no impact on TTFT (supplemental Table 4 and supplemental Figure 1). Notably, however,
among M-CLL subset #2 cases, the presence of del(11q) was associated with significantly shorter TTFT
(13 vs 29 months, P = .03); no such differences were observed among U-CLL subset #2 cases (P = .26;
supplemental Figure 2A-C).
In contrast, non–subset #2/IGHV3-21 cases had significantly longer TTFT compared with subset #2 CLL
(60 vs 22 months, P = .001; Figure 1A), also when limiting the analysis to Binet stage-A cases (P = .01;
supplemental Figure 2D). This was because of the superior outcome of non–subset #2/IGHV3-21 M-CLL
cases (median TTFT 153 months) vs non–subset #2/IGHV3-21 U-CLL cases, which did not differ
significantly from subset #2 or all remaining U-CLL cases utilizing IGHV genes other than IGHV3-21 (30
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4311230/?report=printable
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vs 22 vs 24 months, respectively, P = .4). Given the aforementioned differences in SHM load, we also
investigated separately cases carrying IGHV genes with <97% GI and found again significantly longer
TTFT for non–subset #2/IGHV3-21 vs subset #2 cases (supplemental Figure 3). In multivariate analysis,
U-CLL was the only parameter with independent significance (P = .01; supplemental Table 5), indicating
that the prognosis of non–subset #2/IGHV3-21 cases is associated with SHM status (Figure 1B) rather than
use of a specific IGHV gene and BcR IG as is the case with subset #2.
This conclusion is based on TTFT assessment and also confirmed within early stage patients only. Most
published studies reached an opposite conclusion when assessing OS,10,11,19 which can be considered a
limitation because patients may have been treated differently. That notwithstanding, it is worth mentioning
that we could not discern any impact of SHM status on OS within subset #2, whereas the OS of non–
subset #2/IGHV3-21 cases was influenced by the SHM status (supplemental Figure 4). However,
definitive conclusions regarding OS can be reached only by prospective studies on uniformly treated
patients.
Interestingly, our study also suggests the possibility to further refine prognosis within subset #2, where the
presence of del(11q) within M-CLL subset #2 cases seems to be associated with a more unfavorable
clinical profile. Further investigations are required before reaching definitive conclusions regarding this
issue and, more generally, the precise impact of genetic aberrations (eg, SF3B1 mutations), which are very
frequent in subset #2, yet their prognostic implications remain disputed.17,18
In conclusion, IGHV3-21 gene usage in CLL should not be axiomatically considered as an adverse
prognostic indicator (ie, not included tout court in the stratification algorithm of prospective clinical trials).
Hence, subset #2 emerges as uniformly aggressive, thus contrasting with non–subset #2/IGHV3-21
patients whose prognosis differs depending on SHM status, similar to all other CLL. Consequently, we
argue that knowledge about subset #2 membership is clinically relevant, in particular for stratification
purposes within clinical trials. More generally, our findings also support the concept of stratifying CLL
based on the molecular features of the BcR IG,24 the ideal clonotypic marker, present in every CLL clone
and unaffected by clonal evolution.25
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Table 1
Main clinicobiological features of stereotyped subset #2 and non–subset #2/IGHV3-21 cases
included in the survival analysis
Subset #2 (n = 212) Non–subset #2/ IGHV3-21 (n = 143)
Male

P

132/254, 62%

87/183, 61%

ns

63.5 y

62.2 y

ns

Binet A

72/156, 46%

50/81, 61%

.023

U-CLL

86/212, 40%

84/143, 59%

.0007

CD38 expression

35/92, 38%

31/73, 42%

ns

ZAP70 expression

23/54, 43%

16/33, 48%

ns

del(13q)

50/81, 61%

27/51, 53%

ns

Trisomy 12

5/103, 5%

5/65, 8%

ns

del(11q)

23/109, 21%

10/70, 14%

ns

del(17p)

4/103, 4%

3/69, 4%

ns

TTFT

22 mo

60 mo

.001

TTFT (M-CLL)

23 mo

154 mo

<.0001

TTFT (U-CLL)

19 mo

30 mo

ns

Age (median)

del(13q): isolated deletion of chromosome 13q; ns: nonsignificant. P values in bold indicate statistically significant
differences.
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Figure 1

Kaplan Meier curves for TTFT. (A) Subset #2 exhibits significantly shorter TTFT compared with non–subset
#2/IGHV3-21 CLL. (B) No difference regarding TTFT between non–subset #2/IGHV3-21 cases and the remaining CLL.
Subset #2 exhibits TTFT similar to that of U-CLL independently of IGHV gene mutational status.

Articles from Blood are provided here courtesy of The American Society of Hematology

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4311230/?report=printable

8/8

